Tscan Therapeutics Inc’s recent filing unveils that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.67 million on May 19 ’25. In the deal valued at $1.20 per share,1,388,794 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 6,746,141 shares worth roughly $11.81 million.
Then, Lynx1 Capital Management LP bought 1,200,000 shares, generating $1,440,000 in total proceeds. Upon buying the shares at $1.20, the 10% Owner now owns 7,946,141 shares.
Before that, Lynx1 Capital Management LP bought 100,000 shares. Tscan Therapeutics Inc shares valued at $290,140 were divested by the 10% Owner at a price of $2.90 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,357,347 shares, worth roughly $9.38 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Tuesday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock jump 2.34% to $1.75. Over the last five days, the stock has lost -2.78%. Tscan Therapeutics Inc shares have fallen nearly -74.38% since the year began. Nevertheless, the stocks have fallen -42.43% over the past one year.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2025-07-15, dropping by -0.43 million shares to a total of 1.83 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.27 million shares. There was a decline of -23.71%, which implies that there is a negative sentiment for the stock.
